Alnylam Announces U.S. Food and Drug Administration …
Nov 25, 2024 · Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults ...
Vutrisiran in Patients with Transthyretin Amyloidosis with ...
Aug 30, 2024 · Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. In this double-blind, randomized trial, we assigned patients with...
Alnylam Announces U.S. Food and Drug Administration …
Nov 25, 2024 · About AMVUTTRA® (vutrisiran) AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of mutant and wild-type transthyretin (TTR), addressing the underlying cause of ...
Alnylam Announces U.S. Food and Drug Administration
Nov 25, 2024 · Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Jun 24, 2024 Press Release for Alnylam - Alnylam Pharmaceuticals, …
Jun 24, 2024 · AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of mutant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, AMVUTTRA is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of ...
Alnylam Submits Supplemental New Drug Application (sNDA) to …
Oct 9, 2024 · Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults. As part of the...
Vutrisiran Under Review for Transthyretin Amyloid Cardiomyopathy
Nov 25, 2024 · Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ... News release. Alnylam. November 25, 2024.
FDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM treatment
Nov 25, 2024 · Vutrisiran is the generic name for AMVUTTRA which is currently approved by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis hATTR-PN in adults.
Alnylam reveals positive Phase III results for rare heart disease …
Jun 24, 2024 · Alnylam Pharmaceuticals saw shares of its stock jump by 32% after sharing positive topline results for a late-stage study of its RNA interference (RNAi) therapeutic, vutrisiran, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Alnylam says heart drug succeeds in closely watched study
Jun 24, 2024 · Positive results from a Phase 3 trial of vutrisiran in transthyretin amyloidosis cardiomyopathy come eight months after the FDA rejected another medicine Alnylam developed for the condition.
- Some results have been removed